Tivic Health Systems Bolsa (NASDAQ: TIVC)

Últimas noticias sobre Tivic Health Systems (NASDAQ:TIVC) Bolsa

Tivic Health Systems

Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems Inc

<ul>
<li>Maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the Company's common shares, with 1,507,328 shares repurchased for USD 11,629,758 as of the date hereof. &nbsp;</li>
<li>A period from and including 5 October 2024 to and including 4 October 2025.
<ul>
<li>The share buy-backs will be carried out by way of repurchases in the market, both on the Oslo Stock Exchange and on Nasdaq.</li>
</ul>
</li>
</ul>


News

Buybacks

GOGL

Golden Ocean Group Extends Existing Buy-Back Program With 12 Months

Maryland American Water Receives Commission Approval For Acquisition Of Severn Water Company For ~$1.6M

<p><strong>Levi Strauss &amp; Co. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares are trading lower following the company&#8217;s third-quarter financial results released after Wednesday&#8217;s closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/b41150661/levi-strauss-co-reports-third-quarter-2024-financial-results">details from the report. </a></p>
<p><strong>The Details:</strong> Levi Strauss reported quarterly earnings of 33 cents per share, which beat the analyst consensus estimate of 31 cents. Quarterly revenue came in at $1.516 billion, which missed the analyst consensus estimate of $1.55 billion.</p>
<ul>
<li>DTC (Direct-to-Consumer) net revenues increased 10% on a reported basis and 12% on a constant-currency basis. DTC growth reflected a 12% increase in the U.S. and a 9% increase in Europe.</li>
<li>Wholesale net revenues decreased 6% on a reported basis and 5% on a constant-currency basis. Adjusting for the exit of the Denizen business, wholesale net revenues declined 3%.</li>
<li>Operating margin was 2.0% compared to 2.3% in the same quarter last year inclusive of an impairment charge of $111 million related to the Beyond Yoga acquisition.</li>
<li>Gross margin increased 440 basis points to 60% from 55.6% in the same quarter last year primarily driven by lower product costs and favorable channel and brand mix.</li>
</ul>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/news/24/10/41129365/what-happened-with-rivian-stock-today"><strong>What Happened With Rivian Stock Today?</strong></a></p>
<p>&#8220;The underlying fundamentals of our business are getting stronger, driven by the Levi&#8217;s&#xAE; brand, which grew 5% globally in Q3, a significant acceleration from H1 and the highest revenue growth in two years. We are making progress against our strategic priorities, including double-digit growth in our direct-to-consumer business, continued positive performance in the U.S., and Europe inflecting to growth,&#8221; said <strong>Michelle Gass</strong>, CEO of Levi Strauss &amp; Co.</p>
<p><strong>Outlook:</strong> Levi Strauss sees fiscal year 2024 adjusted earnings at a mid-point of between $1.17 and $1.27 per share, versus the $1.25 estimate. </p>
<p><strong>LEVI Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Levi Strauss shares are down 6.22% after-hours at $19.75 after dropping 2.86% in Wednesday&#8217;s regular trading session.</p>
<p><strong>Read Also:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41104861/elon-musk-tesla-win-dismissal-of-full-self-driving-claims-judge-tosses-lawsuit"><strong>Elon Musk, Tesla Win Dismissal Of Full-Self Driving Claims: Judge Tosses Lawsuit</strong></a></li>
</ul>
<p><em>Photo: Courtesy of Levi Strauss &amp; Co. </em></p>


Earnings

After-Hours Center

Movers

LEVI

Levi Strauss & Co Stock Falls After Mixed Q3 Results: EPS Beat, Revenues Miss

<p>The Lydian Includes 129 Homes And 23K Sq Ft Of Office/Retail Space; Acquisition Financed Through $35M Mortgage Debt, $14.5M In Operating Partnership Units, And Cash</p>


Centerspace Expands Denver Presence With $54M Acquisition Of The Lydian; Completes Redemption Of 6.625% Series C Preferred Shares; YTD ATM Sales Of 1.59M Shares With $113.73M In Gross Proceeds Used For Preferred Share Redemption And Debt Pay Down

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Zscaler</strong>.</p>
<p>Looking at options history for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 55% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $365,000 and 7, calls, for a total amount of $1,123,045.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $135.0 to $230.0 for Zscaler over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zscaler's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zscaler's substantial trades, within a strike price spectrum from $135.0 to $230.0 over the preceding 30 days.</p>
<h3>Zscaler 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727901137_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$11.6</td>
<td>$10.85</td>
<td>$11.25</td>
<td>$180.00</td>
<td>$675.0K</td>
<td>820</td>
<td style="text-align: right;">600</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$11.3</td>
<td>$10.65</td>
<td>$11.0</td>
<td>$135.00</td>
<td>$275.0K</td>
<td>18</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$40.7</td>
<td>$40.55</td>
<td>$40.55</td>
<td>$145.00</td>
<td>$93.2K</td>
<td>108</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$8.1</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$175.00</td>
<td>$90.0K</td>
<td>253</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$38.0</td>
<td>$37.3</td>
<td>$37.3</td>
<td>$150.00</td>
<td>$89.5K</td>
<td>2.6K</td>
<td style="text-align: right;">95</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zscaler</h3>
<p>Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.</p>
<p>Following our analysis of the options activities associated with Zscaler, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Zscaler</h3>
<ul>
<li>With a volume of 1,255,322, the price of ZS is up 1.52% at $169.53. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 54 days.</li>
</ul>
<h3>What Analysts Are Saying About Zscaler</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $206.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Zscaler with a target price of $220.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Zscaler, which currently sits at a price target of $200.<br />
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Strong Buy rating for Zscaler, targeting a price of $235.<br />
&#x2A; Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Zscaler with a target price of $205.<br />
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Neutral rating on Zscaler, which currently sits at a price target of $170. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Zscaler, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Decoding Zscaler's Options Activity: What's the Big Picture?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Accenture</strong>.</p>
<p>Looking at options history for Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 66% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $260,055 and 3, calls, for a total amount of $120,743.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $320.0 and $380.0 for Accenture, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Accenture's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Accenture's significant trades, within a strike price range of $320.0 to $380.0, over the past month.</p>
<h3>Accenture Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727901133_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.7</td>
<td>$33.8</td>
<td>$35.7</td>
<td>$370.00</td>
<td>$89.2K</td>
<td>62</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.7</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$360.00</td>
<td>$56.1K</td>
<td>1.0K</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.5</td>
<td>$1.45</td>
<td>$1.5</td>
<td>$325.00</td>
<td>$47.2K</td>
<td>252</td>
<td style="text-align: right;">331</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$27.7</td>
<td>$26.8</td>
<td>$27.7</td>
<td>$370.00</td>
<td>$38.7K</td>
<td>57</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.6</td>
<td>$33.2</td>
<td>$35.6</td>
<td>$370.00</td>
<td>$35.6K</td>
<td>62</td>
<td style="text-align: right;">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Accenture</h3>
<p>Accenture is a leading global IT-services firm that provides consulting, strategy, and technology and operational services. These services run the gamut from aiding enterprises with digital transformation to procurement services to software system integration. The company provides its IT offerings to a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture employs just under 500,000 people throughout 200 cities in 51 countries.</p>
<p>After a thorough review of the options trading surrounding Accenture, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Accenture</h3>
<ul>
<li>With a volume of 2,228,852, the price of ACN is up 1.22% at $356.29. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>Expert Opinions on Accenture</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $376.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Accenture, which currently sits at a price target of $388.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Accenture with a target price of $376.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Accenture, targeting a price of $329.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Accenture with a target price of $390.<br />
&#x2A; Showing optimism, an analyst from TD Cowen upgrades its rating to Buy with a revised price target of $400. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Accenture with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Spotlight on Accenture: Analyzing the Surge in Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Moderna</strong>.</p>
<p>Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 44 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 29% with bearish.</p>
<p>From the overall spotted trades, 30 are puts, for a total amount of $2,727,271 and 14, calls, for a total amount of $652,606.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $175.0 for Moderna over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1078.22 with a total volume of 29,102.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $40.0 to $175.0 over the last 30 days.</p>
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727901128_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.25</td>
<td>$8.0</td>
<td>$8.05</td>
<td>$55.00</td>
<td>$1.0M</td>
<td>1.4K</td>
<td>1.2K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.9</td>
<td>$22.0</td>
<td>$22.4</td>
<td>$75.00</td>
<td>$232.9K</td>
<td>1.3K</td>
<td>104</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.15</td>
<td>$5.75</td>
<td>$6.05</td>
<td>$50.00</td>
<td>$229.2K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$138.6K</td>
<td>5</td>
<td>198</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$37.4</td>
<td>$37.3</td>
<td>$37.4</td>
<td>$100.00</td>
<td>$127.1K</td>
<td>3.5K</td>
<td>34</td>
</tr>
</tbody>
</table>
</p>
<h3>About Moderna</h3>
<p>Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.</p>
<p>After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 4,087,379, with MRNA's price down by -1.17%, positioned at $63.18.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


MRNA

Moderna Unusual Options Activity For October 02

Management

HTBK

Heritage Commerce Appoints Thomas Sa As COO Of Company And The Bank

<h3>Gainers</h3>
<ul>
<li><strong>Thunder Power Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) stock increased by 15.6% to $0.55 during Wednesday's after-market session. The company's market cap stands at $38.6 million. </li>
<li><strong>Jowell Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) shares increased by 11.16% to $2.27. The company's market cap stands at $4.9 million. </li>
<li><strong>Kaixin Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock increased by 9.55% to $0.37. The market value of their outstanding shares is at $22.3 million. </li>
<li><strong>AYRO</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) shares moved upwards by 4.99% to $0.86. The company's market cap stands at $5.9 million. </li>
<li><strong>Lovesac</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares increased by 4.98% to $27.57. The market value of their outstanding shares is at $428.9 million. </li>
<li><strong>Yoshitsu Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares moved upwards by 4.91% to $0.58. The market value of their outstanding shares is at $24.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Levi Strauss</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares fell 7.0% to $19.58 during Wednesday's after-market session. The company's market cap stands at $7.7 billion. As per the news, the Q3 earnings report came out today. </li>
<li><strong>E-Home Household Service</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock decreased by 3.81% to $1.01. The market value of their outstanding shares is at $8.6 million. </li>
<li><strong>Color Star Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares fell 3.81% to $1.01. The market value of their outstanding shares is at $57.0 million. </li>
<li><strong>Genius Gr</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 3.73% to $0.9. The market value of their outstanding shares is at $19.5 million. </li>
<li><strong>Life Time Group Hldgs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) shares decreased by 3.42% to $23.2. The market value of their outstanding shares is at $4.7 billion. </li>
<li><strong>SRIVARU Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares fell 2.44% to $0.08. The company's market cap stands at $2.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AIEV

AYRO

JWEL

KXIN

LOVE

SVMH

TKLF

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Carmell</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 31.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $9.6 million. </li>
<li><strong>Processa Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares rose 30.07% to $1.73. The market value of their outstanding shares is at $5.6 million. </li>
<li><strong>China Pharma Holdings, Inc. Common Stock</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 8.83% to $0.28. </li>
<li><strong>Eagle Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares increased by 7.94% to $2.31. The market value of their outstanding shares is at $29.9 million. </li>
<li><strong>Bone Biologics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock moved upwards by 7.89% to $1.64. The company's market cap stands at $2.9 million. </li>
<li><strong>Conduit Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 7.36% to $0.1. The market value of their outstanding shares is at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Soligenix</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock declined by 8.6% to $4.45 during Wednesday's after-market session. The company's market cap stands at $10.1 million. </li>
<li><strong>Inspire Veterinary</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 6.34% to $0.28. The company's market cap stands at $2.1 million. </li>
<li><strong>Kairos Pharma</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock decreased by 5.3% to $1.25. The company's market cap stands at $16.0 million. </li>
<li><strong>Gossamer Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock declined by 4.77% to $1.0. The market value of their outstanding shares is at $226.2 million. </li>
<li><strong>Fractyl Health</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares fell 4.75% to $2.21. The market value of their outstanding shares is at $105.9 million. </li>
<li><strong>TNF Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares fell 4.66% to $1.64. The market value of their outstanding shares is at $3.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BBLG

CPHI

CTCX

EGRX

GOSS

GUTS

KAPA

PCSA

SNGX

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Graphex Gr</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock moved upwards by 15.0% to $0.24 during Wednesday's after-market session. The market value of their outstanding shares is at $12.1 million. </li>
<li><strong>Lucas GC</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock rose 3.96% to $1.05. The company's market cap stands at $83.5 million. </li>
<li><strong>VCI Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock increased by 3.94% to $0.14. The market value of their outstanding shares is at $20.4 million. </li>
<li><strong>Hyperscale Data</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares increased by 3.63% to $0.23. The company's market cap stands at $8.7 million. </li>
<li><strong>AgEagle Aerial Sys</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares rose 3.39% to $0.14. The market value of their outstanding shares is at $2.0 million. </li>
<li><strong>Castor Maritime</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) shares moved upwards by 2.93% to $4.43. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Nixxy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) shares declined by 9.5% to $2.1 during Wednesday's after-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li><strong>Professional Diversity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock decreased by 8.81% to $0.67. The market value of their outstanding shares is at $8.5 million. </li>
<li><strong>XCHG</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares declined by 8.68% to $13.26. The company's market cap stands at $786.6 million. </li>
<li><strong>Polar Power</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) stock decreased by 5.0% to $0.49. The market value of their outstanding shares is at $8.6 million. </li>
<li><strong>Surf Air Mobility</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) stock decreased by 4.77% to $1.6. The market value of their outstanding shares is at $20.5 million. </li>
<li><strong>Singularity Future Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) stock declined by 4.57% to $1.67. The company's market cap stands at $5.8 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CTRM

GPUS

GRFX

IPDN

LGCL

NIXX

POLA

SGLY

SRFM

UAVS

VCIG

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>AMTD Digital</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares increased by 33.6% to $5.22 during Wednesday's after-market session. The market value of their outstanding shares is at $1.0 billion. </li>
<li><strong>CCSC Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock moved upwards by 11.06% to $1.6. The company's market cap stands at $18.5 million. </li>
<li><strong>Evolv Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock rose 7.69% to $4.2. The market value of their outstanding shares is at $661.7 million. </li>
<li><strong>Glimpse Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 6.15% to $0.77. The company's market cap stands at $13.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li><strong>Iveda Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) shares moved upwards by 4.34% to $1.68. The market value of their outstanding shares is at $3.7 million. </li>
<li><strong>Yxt.Com Group Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) stock moved upwards by 4.0% to $2.6. The market value of their outstanding shares is at $156.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Infobird Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) shares decreased by 4.2% to $2.06 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li><strong>Ostin Technology Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares fell 3.75% to $0.38. The market value of their outstanding shares is at $5.6 million. </li>
<li><strong>MMTEC</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares fell 3.54% to $0.74. The company's market cap stands at $147.3 million. </li>
<li><strong>Intchains Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) shares decreased by 3.02% to $4.5. The company's market cap stands at $270.0 million. </li>
<li><strong>Netgear</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares decreased by 2.79% to $19.25. The market value of their outstanding shares is at $559.5 million. </li>
<li><strong>BTCS</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock declined by 2.59% to $1.13. The company's market cap stands at $18.2 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BTCS

CCTG

EVLV

IFBD

IVDA

NTGR

VRAR

12 Information Technology Stocks Moving In Wednesday's After-Market Session

WIIM

SPRO

Spero Therapeutics shares are trading higher after the company announced the publication of data from its Phase 1 clinical trial, which assessed the intrapulmonary pharmacokinetics of SPR719.

<p>Plans To Increase Valuation And Regain Compliance; Shares Will Continue Trading With ".BC" Designation Indicating Below Compliance Status; No Immediate Impact On Business Operations Or SEC Reporting Requirements</p>


Know Labs Receives NYSE American Noncompliance Notice For Not Meeting Listing Standards

Biotech

General

Spero Therapeutics Publishes SPR720 Phase 1 Lung Exposure Data In Antimicrobial Agents And Chemotherapy

<p><strong>Ollie&#39;s Bargain Outlet Holdings, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olli#NASDAQ">OLLI</a>) is set to enhance its retail footprint following the acquisition of seven former Big Lots store leases won through a recent bankruptcy auction. This acquisition comes as part of the ongoing restructuring efforts of Big Lots, which included the closure of 143 stores.</p>
<h2>Details of OLLI&#39;s Acquisition of 7 Big Lots&#39; Stores</h2>
<p>Of the seven stores, Ollie&#39;s Bargain has received the final clearance and approval for six stores from the United States Bankruptcy Court for the District of Delaware. The seventh store is expected to receive the necessary approvals soon.</p>
<p>What makes these stores an ideal choice is that these have the required size, situated in prime trade areas and align with OLLI&#39;s commitment to serving value-oriented customers. Not only this but these stores also are located in the Midwest, a region where OLLI sees significant growth potential and has opened a new distribution center.</p>
<p>Similar to the 99 Cent Only stores&#39; acquisition, OLLI&#39;s primary focus is on opening the acquired Big Lots stores while adjusting the schedule for other planned store openings in its pipeline to optimize productivity and reduce pre-opening costs. For fiscal 2024, the company anticipates 50 new stores and two planned closures.</p>
<p>Ollie&#39;s Bargain&#39;s acquisition of former Big Lots stores signifies a strategic growth initiative within the competitive retail landscape. Currently, OLLI operates 541 stores across 31 states. The company&#39;s long-term plan is to operate 1300 stores across the United States.</p>
<h2>What More Should Investors Know About OLLI?</h2>
<p>Ollie&#39;s Bargain business model of &quot;buying cheap and selling cheap&quot;, cost-containment efforts, focus on store productivity and expansion of customer reward program and Ollie&#39;s Army reinforce its position in the industry. Ollie&#39;s Army continues to be a significant sales driver in the second quarter of fiscal 2024 with the increasing membership. The company ended the quarter with 14.5 million active Ollie&#39;s Army members, which accounted for more than 80% of sales. Collectively, these initiatives position the company for sustained growth.</p>
<p>OLLI delivered a strong performance in the second quarter. It emphasizes value-driven merchandise assortments, which allowed the company to seize market opportunities and meet consumer demand effectively. Comparable store sales rose 5.8% in the quarter, driven by growth in transactions and basket size. Ollie&#39;s Bargain has now achieved nine consecutive quarters of comparable store sales growth.</p>
<p>The improved business performance prompted management to lift its fiscal 2024 view. OLLI now expects net sales in the range of $2.276-$2.291 billion compared with $2.257-$2.277 billion stated earlier. Ollie&#39;s Bargain now anticipates comparable store sales to rise in the band of 2.7-3.2% compared with 1.5-2.3% previously stated. The company has revised adjusted EPS to be in the band of $3.22-$3.30, up from the earlier estimated range of $3.18-$3.28.</p>
<h2>How is the Zacks Consensus Estimate Faring for OLLI?</h2>
<p>Reflecting the positive sentiment around OLLI, the Zacks Consensus Estimate for EPS has seen upward revisions. In the past 60 days, analysts have increased their estimates for the current and next fiscal year by 0.3% to $3.28 and 1.1% to $3.72 per share, respectively. These estimates indicate expected year-over-year growth of 12.7% and 13.4%, respectively.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/75/80055.jpg?v=1028948304" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Does OLLI Stock Look Attractive?</h2>
<p>In the past six months, OLLI&#39;s shares have gained 38.5%, outpacing the industry and the S&amp;P 500&#39;s growth of 6.8% and 9.9%, respectively.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/da/80057.jpg?v=2118532209" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>OLLI stock has been a strong performer, but its valuation remains a topic of debate. Currently, the stock trades at a premium relative to the industry, with a price-to-earnings ratio indicating that its growth potential may already be factored into price.</p>
<p>OLLI&#39;s forward 12-month price-to-earnings ratio stands at 26.7X, higher than the industry&#39;s ratio of 18.6X. This suggests that investors are paying a premium compared with the company&#39;s expected earnings growth. OLLI has a Value Score of D.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/70/80056.jpg?v=1422364156" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>How to Play OLLI Stock?</h2>
<p>Ollie&#39;s Bargain is well-positioned to enhance its market presence, drive sales and deliver value to its customers, leading to improved financial performance in the coming quarters. Investors with a long-term horizon may stay invested in this Zacks Rank #3 (Hold) stock but potential investors should look for a better entry point, given its higher valuation.</p>
<h2>Stocks to Consider</h2>
<p>Here, we have highlighted three better-ranked stocks, namely <strong>Sprouts Farmers Market, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfm#NASDAQ">SFM</a>), <strong>Burlington Stores, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/burl#NYSE">BURL</a>) and <strong>Chewy, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chwy#NYSE">CHWY</a>), currently carrying a Zacks Rank # 2 (Buy) each.</p>
<p>Sprouts Farmers engages in the retailing of fresh, natural and organic food products under the Sprouts brand in the United States. SFM has a trailing four-quarter earnings surprise of nearly 12%, on average.</p>
<p>The Zacks Consensus Estimate for Sprouts Farmers&#39; current-fiscal year&#39;s sales and earnings indicates growth of 9.6% and 18.7%, respectively, from the year-ago reported numbers.</p>
<p>Burlington Stores operates as a retailer of branded merchandise in the United States. BURL has a trailing four-quarter earnings surprise of 18.4%, on average.</p>
<p>The Zacks Consensus Estimate for Burlington Stores&#39; current-financial year&#39;s sales and earnings implies a rise of 10.1% and 30.5%, respectively, from the year-earlier reported figures.</p>
<p>Chewy engages in the pure-play e-commerce business in the United States. CHWY has a trailing four-quarter earnings surprise of 50.9%, on average.</p>
<p>The Zacks Consensus Estimate for Chewy&#39;s current-financial year&#39;s sales and earnings indicates an increase of 5.7% and 65.2%, respectively, from the year-ago reported numbers.</p>
<p><a href="https://www.zacks.com/stock/news/2344979/olli-expands-with-7-big-lots-stores-what-more-should-investors-know?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2344979">To read this article on Zacks.com click here.</a></p>


Large Cap

Mid Cap

Analyst Ratings

Trading Ideas

BURL

CHWY

OLLI

OLLI Expands With 7 Big Lots Stores: What More Should Investors Know?

<p><a href="https://x.com/allyversprille/status/1841574905470386647" title="https://x.com/allyversprille/status/1841574905470386647">https://x.com/allyversprille/status/1841574905470386647</a></p>


Bloomberg Reporter Post On X, " FAA has concluded its review of United Airlines which followed a spate of safety incidents at the carrier earlier this year. The review didn't identify "any significant safety issues," the regulator said in a statement to Bloomberg.'

AMZN

NLRB Issues Formal Complaint Against Amazon Affirming That Company Is A Joint Employer Of Its Delivery Service Partner Drivers And Has Legal Duty To Recognize And Bargain With Teamsters Union

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR"><strong>Currenc Group</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 19.07% at $2.49</li>
<li><a href="https://www.benzinga.com/quote/FUAPF"><strong>Global Compliance</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 12.24% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS"><strong>Kaya Holdings</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 10.75% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF"><strong>1933 Industries</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 5.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CRBP"><strong>Corbus Pharmaceuticals</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 4.58% at $20.11</li>
<li><a href="https://www.benzinga.com/quote/CARA"><strong>Cara Therapeutics</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 4.53% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/SOL"><strong>Emeren Group</strong></a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.11% at $2.83</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LMLLF"><strong>Pharmadrug</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 36.87% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBDY"><strong>Target Group</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 17.24% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ELLXF"><strong>Elixinol Wellness</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 16.13% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX"><strong>CNBX Pharmaceuticals</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 6.53% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII"><strong>22nd Century Group</strong></a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 4.89% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/OILFF"><strong>Nextleaf Solutions</strong></a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 4.68% at $0.06</li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cannabis

CARA

CBDY

CNBX

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

ELLXF

FUAPF

KAYS

LMLLF

OILFF

TGIFF

XXII

Cannabis Stock Movers For October 2, 2024

Asset Sales

Levi Strauss Begins Strategic Review For Dockers Brand, Exploring Potential Sale Or Other Strategic Transactions; Bank Of America Retained As Financial Advisor; No Set Deadline Or Guarantee Of Any Outcome

The latest announcement is out from Tivic Health Systems (TIVC). Tivic Health Systems, Inc. has terminated its Fulfillment Services Agreement with ...

Tivic Health Ends Agreement with ALOM to Reduce Costs

Tivic Health Systems (TIVC) has issued an update. At an Annual Meeting held virtually on August 9, 2024, a company's stockholders cast their votes ...

Tivic Health Systems' Key Decisions at Annual Stockholders' Meeting

Tivic Health Systems GAAP EPS of -$0.32, revenue of $0.14M

An update from Tivic Health Systems (TIVC) is now available. Tivic Health Systems, Inc. has publicly disclosed its financial performance for the se...

Tivic Health Systems Q2 Financial Performance Overview

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Tivic Health Systems</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tivc-stock-quote/"><strong>TIVC</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Tivic Health Systems reported earnings per share of -32 cents.</li><li>The company reported revenue of $140,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tivc-stock-earnings-tivic-health-systems-for-q2-of-2024/">TIVC Stock Earnings: Tivic Health Systems Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TIVC Stock Earnings: Tivic Health Systems Reported Results for Q2 2024

Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript

Tivic Health names Lisa Wolf as interim CFO

Tivic Health Systems ( ($TIVC) ) just unveiled an announcement. Tivic Health Systems, Inc. has entered into an agreement with Maxim Group LLC to po...

Tivic Health Systems Initiates Stock Sale and Leadership Transition

TIVC

Press Releases

Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications

Tivic Health: Christina Valauri Appointed to Board of Directors

Tivic Health Expands Intellectual Property Portfolio

BestGrowthStocks.Com Issues a Comprehensive Analysis of Tivic Health Systems Potential Catalysts

Tivic Announces 2024 Annual Meeting of Stockholders

Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

Tivic Reports Second Quarter 2024 Financial Results

Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

Tivic Health Accelerates VNS Commercial Strategy Development

Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Comments

Tivic Health Systems

Noticias

Últimas noticias sobre Tivic Health Systems (NASDAQ:TIVC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL